TB is the second deadliest infectious disease next to COVID-19,and the ninth largest cause of death globally.In2020,there were approximately 9.2 million TB patients worldwide,with approximately 1.2 million HIV-negative deaths and approximately 208,000 HIV-positive deaths from tuberculosis.TB treatments are increasingly facing multi-drug resistance problems and the only TB vaccine for adults was only recently approved in China in June 2021.In light of the public health crisis,the WHO and member states have pledged to decrease TB incidence and death rate by 90% and 95%,respectively,by 2035,indicating significant market demand for tuberculosis vaccines.

REC606 -- Recombinant adult tuberculosis vaccine

• Self-developed, using both the protein engineering platform and the novel adjuvant technology platform, with the potential to generate better safety and immune responses
• Immunogenicity design, expression and purification of the system have been implemented, and animal challenge experiments have been conducted
• Recombinant protein vaccine prepared using a novel adjuvant BFA01(reference AS01)